Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RUEMU E BIRHIRAY

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1295735058
CMS profile
742525
Location
INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$402,031.80

578 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 12; records 201–250 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RUEMU E BIRHIRAY

NPI 1295735058 · CMS profile ID 742525

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

INDIANAPOLIS, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 12; records 201–250 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RUEMU E BIRHIRAY, NPI 1295735058, CMS profile ID 742525. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 12; records 201–250 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RUEMU E BIRHIRAY, NPI 1295735058, CMS profile ID 742525. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 12; records 201–250 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RUEMU E BIRHIRAY, NPI 1295735058, CMS profile ID 742525, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 12; records 201–250 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

578 matching records · $402,031.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 578 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 578.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $19.6309/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694210683 CMS
Puma Biotechnology, Inc. $842.9808/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017295 CMS
Puma Biotechnology, Inc. $20.0008/30/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017317 CMS
AstraZeneca Pharmaceuticals LP $16.7708/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685229683 CMS
Novartis Pharmaceuticals Corporation $22.9608/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134915 CMS
Janssen Biotech, Inc. $3,800.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658334651 CMS
Puma Biotechnology, Inc. $123.9408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017291 CMS
AstraZeneca Pharmaceuticals LP $16.5508/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685301243 CMS
Focal Therapeutics, Inc. $79.5408/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 649946983 CMS
Novartis Pharmaceuticals Corporation $20.5908/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134905 CMS
Pharmacyclics LLC, An AbbVie Company $104.0608/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665709609 CMS
Pharmacyclics LLC, An AbbVie Company $3,000.0008/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665709619 CMS
Pharmacyclics LLC, An AbbVie Company $828.7208/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665709621 CMS
Amgen Inc. $6.7708/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662978837 CMS
Amgen Inc. $2.6308/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662978843 CMS
AstraZeneca Pharmaceuticals LP $16.6408/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685718763 CMS
Janssen Biotech, Inc. $3,300.0008/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658334641 CMS
Janssen Biotech, Inc. $597.4508/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658334645 CMS
Janssen Biotech, Inc. $86.0508/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658334649 CMS
Incyte Corporation $15.1908/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666269813 CMS
Puma Biotechnology, Inc. $3,500.0008/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017293 CMS
Seattle Genetics, Inc. $14.8508/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678804389 CMS
AstraZeneca Pharmaceuticals LP $17.3308/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685502791 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.4208/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700074441 CMS
Novartis Pharmaceuticals Corporation $13.5208/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134817 CMS
Incyte Corporation $7,073.0008/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666269862 CMS
Janssen Biotech, Inc. $27.4108/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658334637 CMS
AstraZeneca Pharmaceuticals LP $12.8308/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685804763 CMS
PFIZER INC. $17.0108/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673281035 CMS
Puma Biotechnology, Inc. $30.2408/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017301 CMS
Puma Biotechnology, Inc. $14.1208/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017303 CMS
PFIZER INC. $2,625.0008/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673821395 CMS
Celgene Corporation $14.6608/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672882085 CMS
Genentech USA, Inc. $10.9308/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681123711 CMS
PFIZER INC. $101.0008/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673277077 CMS
Puma Biotechnology, Inc. $3,500.0008/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017297 CMS
Amgen Inc. $22.0008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662978763 CMS
Novartis Pharmaceuticals Corporation $1,184.1808/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134805 CMS
Novartis Pharmaceuticals Corporation $3,930.0008/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134811 CMS
Novartis Pharmaceuticals Corporation $115.0008/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134813 CMS
Novartis Pharmaceuticals Corporation $15.4908/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134927 CMS
PFIZER INC. $2,525.0008/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673821393 CMS
GENZYME CORPORATION $16.4908/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694118361 CMS
Genentech USA, Inc. $10.7707/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681373439 CMS
Pharmacyclics LLC, An AbbVie Company $600.0007/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665709373 CMS
Puma Biotechnology, Inc. $20.0007/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706017305 CMS
Novartis Pharmaceuticals Corporation $600.0007/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659134799 CMS
Pharmacyclics LLC, An AbbVie Company $1,700.0007/23/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665706199 CMS
Pharmacyclics LLC, An AbbVie Company $17.6807/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665706201 CMS
Pharmacyclics LLC, An AbbVie Company $6.5007/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665706203 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $402,031.80 578
PY2020 $237,046.29 265
PY2021 $475,055.11 376
PY2022 $480,517.51 508
PY2023 $542,099.98 674
PY2024 $483,693.61 610
PY2025 $434,603.82 556

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,101.73 2
PY2025 Principal investigator $302,723.74 30
PY2024 Recipient $2,874.14 8
PY2024 Principal investigator $157,922.00 27
PY2023 Principal investigator $134,202.50 66
PY2022 Principal investigator $73,428.50 35
PY2021 Principal investigator $38,582.48 8
PY2020 Principal investigator $53,982.71 20
PY2019 Principal investigator $134,360.15 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

32 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $4,950.00 12/12/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,071.90 12/04/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184269329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,986.10 12/04/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184269331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.00 12/03/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) No dispute reported 06/30/2026 1184268413
Principal investigator 1 Genentech, Inc. $7,117.00 11/19/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 11/10/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184259291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $700.00 11/10/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184259293
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $250.00 11/10/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184259295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $275.00 11/10/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184259297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,458.60 11/07/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184259125
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $225.00 10/22/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) No dispute reported 06/30/2026 1223287155
Principal investigator 1 Novartis Pharmaceuticals Corporation $196,714.04 10/02/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190311149
Recipient Regeneron Pharmaceuticals, Inc. $835.22 10/02/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184115711
Principal investigator 1 Genentech, Inc. $2,250.00 10/01/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617535
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,287.50 09/18/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) No dispute reported 06/30/2026 1223285662
Recipient Regeneron Pharmaceuticals, Inc. $266.51 09/16/2025 Covered Recipient Physician AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA No dispute reported 06/30/2026 1184115709
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $480.00 08/18/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) No dispute reported 06/30/2026 1223284359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,402.40 07/31/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222880
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,346.80 07/31/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222882
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,039.20 07/31/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184222884
Principal investigator 1 Genentech, Inc. $4,950.00 07/21/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617531
Principal investigator 1 Genentech, Inc. $4,950.00 06/04/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617513
Principal investigator 1 Genentech, Inc. $1,600.00 06/04/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617517
Principal investigator 1 Genentech, Inc. $2,808.00 06/02/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617510
Principal investigator 1 Genentech, Inc. $6,410.00 05/12/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617528
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,071.90 04/15/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184183396
Principal investigator 1 Genentech, Inc. $9,051.00 04/03/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617524
Principal investigator 1 Genentech, Inc. $9,560.00 03/21/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma No dispute reported 06/30/2026 1211617521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,402.40 03/04/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184156674
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,999.00 01/17/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184148175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,971.00 01/17/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184148177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,071.90 01/07/2025 Non-covered Recipient Entity
INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) No dispute reported 06/30/2026 1184145936